Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

Sweeping changes made by RFK Jr at the CDC have weakened the US's immunisation programme, according to former ACIP members.

European biotechs have historically struggled to find capital on the continent, but the funding ecosystem now aims to scale ...

NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.